Moxifloxacin-induced neutropenia in 26-year-old man

Moxifloxacin is a fourth generation widely used fluoroquinolone antibiotic. There are three cases of moxifloxacin-induced neutropenia reported in the literature and we report the fourth case. A 26-year-old man with pneumonia was treated with moxifloxacin because of penicillin allergy. On the sec...

Full description

Saved in:
Bibliographic Details
Main Authors: Tuğba Kula Atik, Emre Ispir, Aykut Aytekin, Ufuk Turhan, Esma Yeniiz, Dilaver Tas, Orhan Bedir
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2018-10-01
Series:Journal of Infection in Developing Countries
Subjects:
Online Access:https://jidc.org/index.php/journal/article/view/10212
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849324277793292288
author Tuğba Kula Atik
Emre Ispir
Aykut Aytekin
Ufuk Turhan
Esma Yeniiz
Dilaver Tas
Orhan Bedir
author_facet Tuğba Kula Atik
Emre Ispir
Aykut Aytekin
Ufuk Turhan
Esma Yeniiz
Dilaver Tas
Orhan Bedir
author_sort Tuğba Kula Atik
collection DOAJ
description Moxifloxacin is a fourth generation widely used fluoroquinolone antibiotic. There are three cases of moxifloxacin-induced neutropenia reported in the literature and we report the fourth case. A 26-year-old man with pneumonia was treated with moxifloxacin because of penicillin allergy. On the second day of therapy, leukopenia [White blood cell (WBC) count 2.7×10³/μL] and neutropenia (neutrophils 1.21×10³/μL) occurred. Rothia mucilaginosa was isolated in sputum culture. On the fourth day of hospitalization moxifloxacin treatment was stopped and clarithromycin 500 mg PO twice daily was started. Leukopenia and neutropenia resolved one day after discontinuation of moxifloxacin that WBC and neutrophil count rose 4.5×10³/μL and 1.97×10³/μL, respectively. On the sixth day of hospitalization, WBC and neutrophil count was 4.3×10³/μL and 2.29×10³/μL, respectively. The immunomodulatory effects of moxifloxacin may result in the changes of WBC count like leukopenia with neutropenia. Moxifloxacin induced neutropenia may be more common and is an important adverse effect. More observational studies about safety profiles of moxifloxacin are needed.
format Article
id doaj-art-0b51de69f19c48149a3e8570559125d9
institution Kabale University
issn 1972-2680
language English
publishDate 2018-10-01
publisher The Journal of Infection in Developing Countries
record_format Article
series Journal of Infection in Developing Countries
spelling doaj-art-0b51de69f19c48149a3e8570559125d92025-08-20T03:48:46ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802018-10-01121010.3855/jidc.10212Moxifloxacin-induced neutropenia in 26-year-old manTuğba Kula Atik0Emre Ispir1Aykut Aytekin2Ufuk Turhan3Esma Yeniiz4Dilaver Tas5Orhan Bedir6Balıkesir Atatürk City Hospital, Balıkesir, TurkeyBalıkesir Atatürk City Hospital, Balıkesir, TurkeyBalikesir State Hospital, Balıkesir, TurkeyBalikesir State Hospital, Balıkesir, TurkeyBalikesir State Hospital, Balıkesir, TurkeySultan Abdülhamid Han Training and Research Hospital, Istanbul, TurkeyGülhane Training and Research Hospital, Ankara, Turkey Moxifloxacin is a fourth generation widely used fluoroquinolone antibiotic. There are three cases of moxifloxacin-induced neutropenia reported in the literature and we report the fourth case. A 26-year-old man with pneumonia was treated with moxifloxacin because of penicillin allergy. On the second day of therapy, leukopenia [White blood cell (WBC) count 2.7×10³/μL] and neutropenia (neutrophils 1.21×10³/μL) occurred. Rothia mucilaginosa was isolated in sputum culture. On the fourth day of hospitalization moxifloxacin treatment was stopped and clarithromycin 500 mg PO twice daily was started. Leukopenia and neutropenia resolved one day after discontinuation of moxifloxacin that WBC and neutrophil count rose 4.5×10³/μL and 1.97×10³/μL, respectively. On the sixth day of hospitalization, WBC and neutrophil count was 4.3×10³/μL and 2.29×10³/μL, respectively. The immunomodulatory effects of moxifloxacin may result in the changes of WBC count like leukopenia with neutropenia. Moxifloxacin induced neutropenia may be more common and is an important adverse effect. More observational studies about safety profiles of moxifloxacin are needed. https://jidc.org/index.php/journal/article/view/10212FluoroquinolonemoxifloxacinneutropeniapneumoniaRothia mucilaginosa
spellingShingle Tuğba Kula Atik
Emre Ispir
Aykut Aytekin
Ufuk Turhan
Esma Yeniiz
Dilaver Tas
Orhan Bedir
Moxifloxacin-induced neutropenia in 26-year-old man
Journal of Infection in Developing Countries
Fluoroquinolone
moxifloxacin
neutropenia
pneumonia
Rothia mucilaginosa
title Moxifloxacin-induced neutropenia in 26-year-old man
title_full Moxifloxacin-induced neutropenia in 26-year-old man
title_fullStr Moxifloxacin-induced neutropenia in 26-year-old man
title_full_unstemmed Moxifloxacin-induced neutropenia in 26-year-old man
title_short Moxifloxacin-induced neutropenia in 26-year-old man
title_sort moxifloxacin induced neutropenia in 26 year old man
topic Fluoroquinolone
moxifloxacin
neutropenia
pneumonia
Rothia mucilaginosa
url https://jidc.org/index.php/journal/article/view/10212
work_keys_str_mv AT tugbakulaatik moxifloxacininducedneutropeniain26yearoldman
AT emreispir moxifloxacininducedneutropeniain26yearoldman
AT aykutaytekin moxifloxacininducedneutropeniain26yearoldman
AT ufukturhan moxifloxacininducedneutropeniain26yearoldman
AT esmayeniiz moxifloxacininducedneutropeniain26yearoldman
AT dilavertas moxifloxacininducedneutropeniain26yearoldman
AT orhanbedir moxifloxacininducedneutropeniain26yearoldman